Nrf2 Inhibition Overcomes Regorafenib Resistance in Sorafenib-Resistant Liver Cancer Cells: The Resistant Cells Showed a 4.9-Fold Higher IC50 at 48 Hours in Scientific Reports, Published November 13
Scientific Reports published a study of drug resistance in hepatocellular carcinoma cells on November 13, 2026. The paper, by Kahraman, Kiriş, İnci and co-authors, carries digital object identifier 10.1038/s41598-026-79897-x, was received on September 8, 2025 and accepted on November 4, 2026. The study investigated whether inhibition of the Nrf2 pathway could enhance the anticancer activity of regorafenib in sorafenib-resistant liver cancer cell lines. In HuH-7 sorafenib-resistant cells, IC50 values following regorafenib treatment were 4.9-fold and 2-fold higher at 48 and 72 hours, respectively, compared to parental HuH-7 cells. Suppression of the Nrf2 pathway in the resistant cells resulted in a significant reduction in cell viability and ERK1/2 phosphorylation, along with increased cleaved caspase-3 expression, elevated intracellular reactive oxygen species levels, and decreased cell migration. The authors concluded that liver cancer cells which developed resistance to sorafenib also exhibited resistance to regorafenib, and that this resistance could be overcome by inhibition of the Nrf2 signaling pathway.
(Source: Scientific)
Source: Scientific
Published by GSM · USA (original Chinese edition)
Photo: 图：显微镜下的癌细胞影像。Nevena Morel, with my team Lisa Bourne and Nicolas Jacquemin，CC BY 4.0，经 Wikimedia Commons。 / Photo: Nevena Morel, with my team Lisa Bourne and Nicolas Jacquemin, CC BY 4.0, via Wikimedia Commons.
Silicon Carbide Nanomaterials in Disc Brake Pads: 0.5% Loading Raised Average Brake Force by Up to 19%, With Fade Resistance Up to 130°C2026-11-14
PEBA-PEMA Blend Membrane Separates 1-Butanol With Flux of 0.19 kg/m2/h and Separation Factor of 15.5 at 5 Percent PEMA, Published in Scientific Reports on November 132026-11-14